Molecular and Functional Characterization of Three Different Postzygotic Mutations in PIK3CA-Related Overgrowth Spectrum (PROS) Patients: Effects on PI3K/AKT/mTOR Signaling and Sensitivity to PIK3 Inhibitors

PLoS ONE - United States
doi 10.1371/journal.pone.0123092
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Public Library of Science (PLoS)

Related search

In Vitro Efficacy of ARQ 092, an Allosteric AKT Inhibitor, on Primary Fibroblast Cells Derived From Patients With PIK3CA-related Overgrowth Spectrum (PROS)

Neurogenetics
Molecular NeuroscienceGeneticsCellular
2018English

One of the First Cases With PIK3CA-related Overgrowth Spectrum (PROS) in Saudi Arabia: A Case Report and Literature Review

Cureus
2020English

Status of PI3K/Akt/mTOR Pathway Inhibitors in Lymphoma

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2014English

Preclinical Testing of PI3K/AKT/mTOR Signaling Inhibitors in a Mouse Model of Ovarian Endometrioid Adenocarcinoma

Clinical Cancer Research
Cancer ResearchOncology
2011English

Effect of PI3K/Akt/mTOR Signaling Pathway on JNK3 in Parkinsonian Rats

Experimental and Therapeutic Medicine
MedicineCancer ResearchImmunologyMicrobiology
2018English

Combination of PI3K/mTOR Inhibitors: Antitumor Activity and Molecular Correlates

Cancer Research
Cancer ResearchOncology
2011English

Erratum To: PI3K/Akt/mTOR Signaling in Medullary Thyroid Cancer: A Promising Molecular Target for Cancer Therapy

Endocrine
2016English

Activation of WNT/β-catenin Signaling Results in Resistance to a Dual PI3K/mTOR Inhibitor in Colorectal Cancer Cells Harboring PIK3CA Mutations

International Journal of Cancer
Cancer ResearchOncology
2018English

mTORC1 Inhibition Is Required for Sensitivity to PI3K P110 Inhibitors in PIK3CA-Mutant Breast Cancer

Science Translational Medicine
Medicine
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy